WS
SGMO

Wedbush Securities’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Wedbush Securities’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14,880
Closed -$131K – 867
2017
Q2 		$131K Sell
14,880
-26,215
-64% -$168K 0.02% 758
2017
Q1 		$214K Sell
41,095
-15,395
-27% -$61.8K 0.03% 664
2016
Q4 		$172K Sell
56,490
-23,530
-29% -$85.7K 0.03% 685
2016
Q3 		$370K Buy
80,020
+18,450
+30% +$93.8K 0.06% 431
2016
Q2 		$356K Sell
61,570
-500
-0.8% -$3.19K 0.06% 389
2016
Q1 		$376K Sell
62,070
-300
-0.5% -$1.8K 0.07% 337
2015
Q4 		$569K Sell
62,370
-24,710
-28% -$190K 0.1% 217
2015
Q3 		$491K Buy
87,080
+10,185
+13% +$84K 0.1% 236
2015
Q2 		$853K Buy
76,895
+2,880
+4% +$37.1K 0.16% 152
2015
Q1 		$1.16M Buy
74,015
+37,035
+100% +$573K 0.2% 110
2014
Q4 		$562K Buy
36,980
+570
+2% +$6.92K 0.09% 238
2014
Q3 		$393K Buy
+36,410
New +$476K 0.06% 326

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wedbush Securities's SGMO Position: Q3 2017 in Review

Wedbush Securities sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2017, closing a stake of 14,880 shares — an estimated $131K sold.

Wedbush Securities first reported a position in SGMO in Q3 2014 and held it in 12 quarters. The position peaked at $1.16M in Q1 2015. 148 funds tracked by Wall St. Rank hold SGMO as of Q3 2017.

  • Wedbush Securities reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2017 after selling out during the quarter.
  • Wedbush Securities sold 14,880 SANGAMO THERAPEUTICS INC shares in Q3 2017, an estimated $131K.
  • Wedbush Securities first reported a position in SANGAMO THERAPEUTICS INC in Q3 2014 and held it in 12 quarters.
  • Wedbush Securities's SANGAMO THERAPEUTICS INC position peaked at $1.16M in Q1 2015.
  • 148 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2017.

Based on Wedbush Securities's 13F filing for Q3 2017, filed 31 Oct 2017.